Lecia Bushak is a Senior Reporter at MM+M, focusing on health care news. With a background in journalism and production at local NPR and PBS stations, Lecia brings a unique perspective to her reporting. Her work has appeared in publications such as Campaign US and PRWeek, covering topics ranging from mental health influencers to pharmaceutical industry news.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Not enough data
Lecia Bushak's coverage primarily focuses on the healthcare and pharmaceutical industry, with a specific emphasis on health trends, medical research, and healthcare marketing. Her articles often contain press releases and cite data, indicating that she values factual information from reliable sources.
Given her focus on national coverage in the United States, Lecia would likely be receptive to pitches related to significant developments or trends in the US healthcare and pharmaceutical sectors. She may also be interested in insights from experts within these industries who can provide valuable commentary based on credible data.
Pitches should aim to provide unique perspectives or access to exclusive data that aligns with ongoing health trends or recent developments within the pharmaceutical industry for increased chances of engagement.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Flu vaccinations declined 2% between 2023 and 2024. The CDC battling that drop with its updated Wild to Mild campaign.
Life sciences and healthcare companies will have to focus on seeing consumers as more than patients, according to a recent industry outlook.
TikTokers are going all out to maximize their sleep, buying up magnesium supplements, mouth tape and organic cotton sheets. But does the viral trend work?
Only 13 states currently offer Medicaid coverage for GLP-1 drugs, but the number of prescriptions and overall spending has increased significantly since 2019.
In addition to the Trump presidential win, several states voted on key healthcare measures — including 11 abortion measures that could have long-lasting impacts on reproductive rights.
From drug pricing to reforming the drug regulatory process, Trump's re-election has plenty of implications for the pharma industry.
A Trinity Life Sciences report found that more pharma product launches were successful in 2023 than the year before. Here are the factors driving that success.
AstraZeneca announced it would invest $3.5 billion into new research and development facilities in the U.S.
BioNTech is investing in a promising space in oncology by acquiring Biotheus' PD-L1 and VEGF bispecific antibody.
As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it's investing in a new cancer drug from LaNova.
(833) 317-6278 
